Dr. Kenneth John Kirk, MD Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 6506 E 89th Pl, Tulsa, OK 74133 Phone: 918-494-2051 Fax: 918-592-2377 |
Dr. Vishal Aggarwal, MD Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 3336 E 32 Street, 200, Tulsa, OK 74135 Phone: 918-742-4900 Fax: 918-742-4900 |
Chandini Sharma, MD Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 2025 E 71st St, Tulsa, OK 74136 Phone: 918-561-6642 Fax: 918-561-6647 |
News Archive
The people of Michigan elected the members of the state Senate to be leaders, not vacationers. Unfortunately, the Senate forgot that Thursday and adjourned for its summer vacation. It left Lansing without voting on a bill that would provide health care coverage to nearly half a million working Michiganders. Ensuring access to affordable, quality health care is one of the most significant challenges facing Michigan. The Healthy Michigan plan developed over the past several months is a plan that addresses many of the state's needs and reflects the state's values (Gov. Rick Snyder, 6/23).
A study by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences and the Department of Pharmacology at the University of California, San Diego, shows that a protein called MCL-1, which promotes cell survival, is essential for normal heart function.
A diabetes epidemic is affecting First Nations people, especially women in their prime reproductive years, according to a new study in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/embargo/cmaj090846.pdf.
As thousands of people plan getaways for the fall and winter travel seasons, easy access to healthcare is a concern for many travelers with chronic health conditions who require life-sustaining treatments. Twenty-six million Americans suffer from chronic kidney disease, and more than 355,000 of them require dialysis every few days to stay alive.
YM BioSciences Inc., a drug development company advancing a diverse portfolio of hematology and cancer related products, today announced the pricing of 35,000,000 common shares at US$2.00 per common share in its previously announced underwritten public offering.
› Verified 6 days ago